Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew…
PARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology…
Record Gross Revenues of $9.0 million (+101% vs Q2 2022).Positive Adjusted EBITDA1 of $1.1 million (+$2.7 million vs Q2 2022).Positive…
AI software adds powerful diagnostic monitoring and assessment features and benefits.VANCOUVER, BC / ACCESSWIRE / July 17, 2023 / UniDoc…
Toronto, Ontario--(Newsfile Corp. - July 17, 2023) - Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) ("Justera" or the…
Figure 1 Acumen Pharmaceuticals, Inc. Figure 2 Acumen Pharmaceuticals, Inc.Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating…
TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a…
BUFFALO, NY / ACCESSWIRE / July 14, 2023 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rightsThree new intellectual property rights added to…